Skip to main content

Table 3 Predicting models of remission at time point 2, extended remission and durable remission by multivariable logistic regression analyses (N = 104 patients)

From: Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study

Clinical features present at T1 Model 1: remissiona at T2 (N = 48) Model 2: extended remissiona (N = 31) Model 3: durable remissiona (N = 13)
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Increased CKb - - - 3.18 1.17–8.67 .024* - - -
Facial erythemab - - - - - - 0.11 0.01–0.81 .030*
Digital ulcersb - - - 0.25 0.08–0.77 .015* - - -
Trombocytopheniab, c 0.05 0.01–-0.44 .006** - - - - - -
FVC % pred (pr 10%) 1.37 1.04–1.79 .026* 1.56 1.13–2.16 .007** 1.71 1.04–2.80 .033*
NSAID medication - - - - - - 0.05 0.00–0.73 .028*
Negative anti-RNP - - - - - - 15.0 1.97–113.59 .009**
  1. Area under receiver operating curve (ROC) was 73% for Model 1, 76% for Model 2 and 83% for Model 3
  2. T1 time point 1, T2 time point 2, CK creatine kinase, FVC % pred percentage of predicted forced vital capacity, NSAIDs nonsteroidal anti-inflammatory drugs, anti-RNP anti-ribonucleoprotein, ROC receiver operating characteristic
  3. * P <.05; ** P <.01
  4. aIncludes patients in remission both on and off therapy; medications allowed were hydroxychloroquine, NSAIDs, corticosteroids at ≤ 5 mg daily, calcium channel blockers, methotrexate, mycophenolate and azathioprine
  5. bEver present at T1
  6. cThrombocytes <100 × 109 platelets/L